Theravance Biopharma Inc Live Stock Price Today, Share Analysis and Chart

Name: Theravance Biopharma Inc: Is Infosys Ltd. worth buying?
Item: Theravance Biopharma Inc
Rating: 2.590791625
Author: Trendlyne DVM scores

Mid-range Performer

about

Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalatio...

16.22 -0.29 (-1.76%)

79.42% Gain from 52W Low

556.2K

XNAS Volume

XNAS 15 May, 2026 5:30 PM (EDT)

Board Meeting

The next board meeting for Theravance Biopharma Inc is on 19 May 2026 for the purpose of Theravance Biopharma Inc Annual General Meeting for 2026 See details

Medium Financial Strength

50.0 / 100

Affordable Valuation

61.3 / 100

Technically Neutral

45.9 / 100

Mid-range Performer These stocks have affordable valuations, but mid range financials and momentum View Similar Embed DVM

1Yr Price target upside is 6%

5 analysts

Theravance Biopharma Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Theravance Biopharma Inc Live Stock Price Today, Share Analysis and Chart

Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalatio...

79.42% Gain from 52W Low

SWOT Analysis

Theravance Biopharma Inc Live Price Chart